Sanofi’s CEO, Olivier Brandicourt takes stock of its Biotech pipeline

03/08/2015 - 3 minutes

Olivier Brandicourt, new CEO of Sanofi since last April, has been interviewed by EuroBusiness Media on the company’s last results. The successor of Chris Viehbacher took the opportunity to show the good results made by its Biotech pipeline.

Sanofi q2 2015 results.001.jpg.001

Genzyme, the rare diseases arm of Sanofi, was an important growth driver again this quarter. Total sales of the Rare Diseases franchise were 647 million euros, driven by the sustained success of key brands -Cerezyme, Fabrazyme, and Myozyme- but also the recent launch of Cerdelga, the only first-line oral therapy for Gaucher Disease. In Multiple Sclerosis, Genzyme reported another quarter of exceptional commercial success with over 1 billion euros of sales expected this year.

Sanofi’s growth was also supported by €700 million of sales made by Merial, the Animal Health business of Sanofi which scored its highest quarterly sales ever. The vaccines branch, under Sanofi Pasteur’s flag, came back to growth in the second quarter with sales up to 8.6% led by influenza vaccines and booster vaccines.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: